Skip Navigation

European Heart Journal 1995 16(2):177-183;
Copyright © 1995 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by KORNOWSKI, R.
Right arrow Articles by BATTLER, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by KORNOWSKI, R.
Right arrow Articles by BATTLER, A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1995 The European Society of Cardiology

Beneficial effect of nitroglycerin on arterial rethrombosis after thrombolysis

Results from a rabbit thrombosis model

R. KORNOWSKI, A. CHERNINE, D. HASDAI, Z. OVADIA and A. BATTLER

The Neufeld Cardiac Research Institute, Sackler Faculty of Medicine Tel-Aviv University, Tel-Aviv, Israel

Received 17 February 1994; accepted 16 August 1994.

Correspondence: Ran Kornowski, MD, Neufeld Cardiac Research Insitute, Sheba Medical Center, Tel Hashomer 52621, Israel.

Abstract

Background: Although nitroglycerin (NTG) is commonly administered to patients with acute myocardial infarction, its effect on concomitant thrombolytic therapy has not been fully elucidated. We examined whether NTG administration further optimizes thrombolysis with rt-PA, combined with aspirin and heparin.

Methods and Results: Blood clots were produced in a rabbit femoral artery with endothelial damage and distal stenosis. rt-PA was administered in repeated bolus i. v. injections of 0.3 mg. kg–1 every 10 min for 50 min. Femoral artery flow was measured continuously for 2 h.

Fourteen rabbits were randomized into two groups (group A and B), both receiving aspirin (i.v. 17 mg. kg–1) and heparin (i. v. 200 units. kg–1) prior to the first rt-PA bolus injection. NTG was administered in group B only, 10 min prior to the first rt-PA bolus, at 10 µg. kg–1. min–1 for 130 min. Reperfusion at the end of the 120 min observation period occurred in 5/7 group A and 6/7 group B rabbits (P–ns). In 3/7 group A rabbits, re-flow was achieved but persistent re-occlusion subsequently developed in 1/3 and oscillatory re-flow and re-occlusion cycles (cyclic re-flow) with subsequent patency developed in the remaining two rabbits. These flow patterns were not observed in any of group B rabbits.

Overall patency duration was significantly prolonged with NTG (group B; 578/840 min) compared to controls (group A; 258/840 min) (P<0.001). The mean recanalization time (group A; 30.8 ± 9.3 vs group B; 22.5 ± 4.7 min, P–0.16) as well as mean rt-PA boluses needed to achieve complete recanalization (group A; 4.3 ±0.7 vs group B; 3.3 ± 0.6 boluses/rabbit, P–0.3) did not differ between groups. However, NTG infusion was associated with increased restored femoral flow following recanalization (expressed as % of stenotic flow value over observation time) compared to control group (P–0.025 by repeated measures ANOVA).

Conclusion: Adding NTG to a thrombolytic regimen with rt-PA, aspirin and heparin increases the magnitude of restored flow and total patency duration following recanalization in a rabbit model of arterial thrombosis.

Key Words: Nitroglycerin • thrombolysis • t-PA • heparin • aspirin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur Heart JHome page
J Gunn and D Cumberland
Stent coatings and local drug delivery. State of the art
Eur. Heart J., December 1, 1999; 20(23): 1693 - 1700.
[PDF]


Home page
StrokeHome page
M. M. Bednar and C. E. Gross
Antiplatelet Therapy in Acute Cerebral Ischemia
Stroke, April 1, 1999; 30(4): 887 - 893.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.